A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy

Aust N Z J Obstet Gynaecol. 2011 Oct;51(5):452-4. doi: 10.1111/j.1479-828X.2011.01346.x. Epub 2011 Aug 2.

Abstract

Cyclophosphamide treatment can cause premature ovarian failure. This pilot study evaluates the protective effect of the gonadotrophin releasing hormone (GnRH) antagonist, cetrorelix, on ovarian function, when used during cyclophosphamide chemotherapy in women aged 18-35. Primary outcomes measured were serum follicle stimulating hormone (FSH) and inhibin prior to and at 6 and 12 months after chemotherapy. Secondary outcomes were hormonal evidence of a suppressive effect and the side effect profile.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Autoimmune Diseases / drug therapy
  • Breast Neoplasms / drug therapy
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / pharmacology
  • Female
  • Fertility Preservation
  • Follicle Stimulating Hormone / blood
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / pharmacology
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Hormone Antagonists / pharmacology
  • Hormone Antagonists / therapeutic use*
  • Humans
  • Inhibins / blood
  • Lymphoma / drug therapy
  • Organs at Risk / physiology
  • Ovary / drug effects
  • Ovary / physiology*
  • Pilot Projects
  • Primary Ovarian Insufficiency / chemically induced*
  • Primary Ovarian Insufficiency / prevention & control*
  • Young Adult

Substances

  • Antineoplastic Agents
  • Hormone Antagonists
  • Gonadotropin-Releasing Hormone
  • Inhibins
  • Cyclophosphamide
  • Follicle Stimulating Hormone
  • cetrorelix